8-K
filed December 10, 2025, 6:59 PM ET
ticker HURA
CIK 0001498382
other material
confidence high
sentiment negative
materiality 0.75
TuHURA Biosciences prices $15.6M registered direct offering of stock and warrants in three tranches
TuHURA Biosciences, Inc./NV
- TuHURA prices registered direct offering of 9.46M shares and Series A/B warrants at $1.65/unit; warrants exercisable at $1.95 after six months.
- First closing $8.6M on Dec 10; second $5M by Jan 30, 2026; third $2M by Feb 27, 2026; total gross ~$15.6M.
- Net proceeds for working capital and to repay $3.4M bridge note (3%/mo, due Dec 31, 2025) to Matthew Nachtrab Revocable Trust.
- 30-day lock-up for directors/officers; 30-day halt on equity issuance; 6-month ban on variable rate transactions.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TuHURA Biosciences, Inc./NV entered into Purchase Agreement with certain investors (collectively, the "Purchasers") (effective 2025-12-09).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors (collectively, the "Purchasers")
- Effective
- 2025-12-09
Exact text from the filing
On December 9, 2025, TuHURA Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (collectively, the “Purchasers”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TuHURA Biosciences, Inc./NV entered into Engagement Letter with H.C. Wainwright & Co., LLC.
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
Exact text from the filing
Pursuant to an Engagement Letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“HCW”), the Company agreed to pay HCW, as exclusive lead placement agent, and Rodman & Renshaw LLC, as co-placement agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds raised in the First Closing, (ii) a cash fee equal to 2.0% of the aggregate gross proceeds raised in the Second Closing and Third Closing, (iii) certain expenses including reasonable fees and expenses of counsel in an amount not to exceed $100,000, and (iv) $25,000 for non-accountable expenses.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.7
TuHURA Biosciences, Inc./NV entered into Side Letter with K&V Investment One LLC (effective 2025-12-09).
- Action
- entry
- Counterparty
- K&V Investment One LLC
- Effective
- 2025-12-09
Exact text from the filing
On the same date, the Company and K&V Investment One LLC (“K&V”), a Purchaser in the Offering, entered into a side letter to the Purchase Agreement (the “Side Letter”)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.